logo-loader
viewOpen Orphan Plc

Amryt Pharma co-founder welcomes 'transformational' Aegerion acquisition

Open Orphan PLC (LON:ORPH) chief executive Cathal Friel co-founded Amryt Pharma PLC (LON:AMYT) along with current CEO Joe Wiley and gives his view on the  acquisition of Aegerion Pharmaceuticals Inc.

The merger creates a group with revenues of $136.5mln in 2018 and re-unites the Lojuxta cholesterol treatment under one roof.

Quick facts: Open Orphan Plc

Price: 6.7 GBX

AIM:ORPH
Market: AIM
Market Cap: £17.06 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan Plc named herein, including the promotion by the Company of Open Orphan Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Open Orphan's Maurice Treacy talks genomics and its health...

Open Orphan PLC's (LON:ORPH) chief commercial officer Maurice Treacy caught up with Proactive London's Andrew Scott for a chat on their health databank. Also up for discussion is how Genomic Orphan Health data will work and how important GDPR is to ensure privacy and security.

on 19/9/19

2 min read